Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

ESSENCE is a double-blinded, 240-week study that involves 1,200 adults with MASH and stage two or three liver fibrosis.

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, ...

Novo Nordisk (NVO) stock gains as its weight loss drug succeeds in Phase 3 trial for the liver disease, MASH hurting Eli ...

Bagsværd, Denmark Tuesday, November 5, 2024, 10:00 Hrs [IST] ...

Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial ...

Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

Shares of companies developing therapies for the liver disease metabolic steatohepatitis, or MASH, are rallying after Novo Nordisk (NVO) said ...